Home   Chapter Home   Jobs   Conferences   Fellowships   Books



Advertisement

Lymphoma - Non B cell neoplasms

T/NK cell disorders

Non-B, non-T lymphoblastic lymphoma


Reviewer: Dragos Luca, M.D. (see Reviewers page)
Revised: 27 September 2011, last major update September 2011
Copyright: (c) 2001-2011, PathologyOutlines.com, Inc.

Terminology
=========================================================================

● Includes CD7+ stem cell lymphoma (CD7+, CD4-, CD56-, CD33 variable), blastic NK lymphoma (CD56+, CD4-, CD33-, CD123-, CD7 variable, see above), myeloid/NK precursor leukemia (CD4-, CD7+, CD33+, CD56+), CD4+/CD56+ hematodermic malignancy (also CD33-, CD123+, CD7 variable, Am J Surg Pathol 2003;27:1366)
CD7+ stem cell leukemia: CD7+ but no other lineage marker expressed; frequently presents with mediastinal mass and bone marrow invasion; may convert to AML

Treatment and prognosis
=========================================================================

● May have poorer prognosis than T-cell lymphoblastic lymphoma

Negative stains
=========================================================================

● B-cell markers (CD19, CD20 and CD79a), surface CD3

End of Lymphoma - Non B cell neoplasms > T/NK cell disorders > Non-B, non-T lymphoblastic lymphoma


This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).